Genespire announces that GENE202 has been granted Orphan Drug Designation by the FDA and EC for the treatment of methylmalonic acidemia by genespire | Jan 20, 2026 | News
Preclinical insights into dosing for first-in-human in vivo liver-directed gene therapy for MMA delivered in an oral presentation at the ASGCT Annual Meeting by genespire | May 14, 2025 | News
Genespire announces oral presentation at the ASGCT Annual Meeting detailing preclinical insights into dosing for first-in-human in vivo liver-directed ISLV gene therapy for MMA by genespire | May 8, 2025 | News
The AstraZeneca acquisition of EsoBiotec – important validation for Genespire’s lentiviral vector platform by genespire | Mar 31, 2025 | News
